Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Sevelamer, chapter 2

Genzyme Corp.'s Renagel sevelamer hydrochloride dominates the market for phosphate binders based on its ability to control serum phosphate without causing metal accumulation or calcification. But it isn't perfect. GENZ believes that its next-generation product, Renvela sevelamer carbonate, which was approved by FDA last week, will retain the advantages of Renagel without its disadvantages.

The company plans to market both products, keeping patients who are well managed with Renagel on Renagel. New patients will start

Read the full 746 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE